Analysis of Factors Contributing to Adverse Events and Evaluation of Their Impact on Prognosis in Metastatic Renal Cell Carcinoma Patients—Real-World Experience in a Single-Center Retrospective Study and Narrative Review
Piotr Domański,
Mateusz Piętak,
Szymon Staneta,
Weronika Fortuniak,
Barbara Kruczyk,
Adam Kobiernik,
Piotr Bakuła,
Anna Mydlak,
Tomasz Demkow,
Bożena Sikora-Kupis,
Paulina Dumnicka,
Jakub Kucharz
Affiliations
Piotr Domański
Department of Experimental Immunotherapy, Maria Sklodowska-Curie National Research Institute of Oncology Roentgena 5, 02-781 Warsaw, Poland
Mateusz Piętak
Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Roentgena 5, 02-781 Warsaw, Poland
Szymon Staneta
Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Roentgena 5, 02-781 Warsaw, Poland
Weronika Fortuniak
Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Roentgena 5, 02-781 Warsaw, Poland
Barbara Kruczyk
Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Roentgena 5, 02-781 Warsaw, Poland
Adam Kobiernik
Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Roentgena 5, 02-781 Warsaw, Poland
Piotr Bakuła
Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Roentgena 5, 02-781 Warsaw, Poland
Anna Mydlak
Department of Head and Neck Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Roentgena 5, 02-781 Warsaw, Poland
Tomasz Demkow
Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Roentgena 5, 02-781 Warsaw, Poland
Bożena Sikora-Kupis
Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Roentgena 5, 02-781 Warsaw, Poland
Paulina Dumnicka
Chair of Biochemistry, Jagiellonian University Medical College, 31-034 Kraków, Poland
Jakub Kucharz
Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Roentgena 5, 02-781 Warsaw, Poland
Background and Objectives: More than 430,000 new cases of renal cell carcinoma (RCC) were reported in 2020. Clear cell RCC, which occurs in 80% of cases, is often associated with mutations in the VHL gene, leading to dysregulation of hypoxia-induced transcription factors pathways and carcinogenesis. The purpose of this study is to examine the adverse events (AEs) of cabozantinib treatment and the relationship between individual patient factors and the frequency of their occurrence in detail. Materials and Methods: Seventy-one patients with metastatic RCC were treated with second or further lines of cabozantinib at the Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research Institute of Oncology. Comprehensive data, including demographics, clinicopathological factors, and AEs, were collected from January 2017 to June 2021. This study evaluated the impact of various patient-related factors on the rate of adverse events and treatment tolerance using a Cox proportional hazards model. Results: Cabozantinib-induced AEs were significantly associated with body mass index (BMI), body surface area (BSA), IMDC prognostic score, and treatment line. Notably, patients receiving cabozantinib post-tyrosine kinase inhibitors reported fewer AEs. Dose reduction was unrelated to adverse event frequency, but patients requiring dose reduction were characterized with lower body mass and BSA but not BMI. Conclusions: The factors described make it possible to predict the incidence of AEs, which allows for faster detection and easier management, especially in the high-risk group. AEs should be reported in detail in real-world studies, as their occurrence has a significant impact on prognosis.